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Abstract
Introduction: Cytological material obtained from Fine Needle Aspiration Biopsy (FNAB) does not permit us to distinguish between fol-
licular carcinomas, adenomas, and hyperplastic nodules. The limitations of the method are: lack of possibility to assess the presence of 
tumour capsule, eventual capsular invasion, and angioinvasion. An unequivocal conclusion of whether what we have to deal with is 
a neoplastic or benign lesion is possible only after histopathological examination. The aim of the study was to confirm justification for 
using the term “Suspicious for Follicular Neoplasm” (SFN) in cytological diagnostics of thyroid carcinoma.
Material and methods: Three hundred and fifty-two primary SFN FNAB diagnoses (diagnostic category IV [DC IV] — according to 
Bethesda System) obtained from 2010 to 2015 in the Institute of Oncology in Gliwice were analysed, and their correlation with histo-
pathological diagnoses was verified.
Results: In the Institute of Oncology in Gliwice, 352 primary SFN diagnoses (diagnostic category IV [DC IV] — according to Bethesda 
System) were established. Surgical treatment was undertaken after first FNAB in six cases, giving confirmation of a neoplasm in five cases, 
one of which was a follicular carcinoma. Second FNAB performed in 90 patients confirmed DC IV diagnosis in 53 cases. Third FNAB con-
cerned 26 patients, providing another 14 diagnoses of DC IV. 26 out of 352 patients were subjected to surgery, and then histopathological 
examination confirmed a neoplasm in 19 cases (which comprises 73%), five of which were carcinomas.
Conclusions: High positive predictive value PPV = 73% of SFN diagnosis justifies undertaking surgical treatment in any case of this 
diagnosis. (Endokrynol Pol 2016; 67 (1): 17–22)
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Streszczenie
Wstęp: Materiał cytologiczny biopsji aspiracyjnej cienkoigłowej (BAC) tarczycy nie pozwala na zróżnicowanie raków pęcherzykowych, 
gruczolaków i guzków rozrostowych. Ograniczeniem metody jest brak możliwości określenia obecności torebki guza, jej ewentualnego 
nacieku oraz angioinwazji. Jednoznaczne rozstrzygnięcie czy mamy do czynienia ze zmianą nowotworową czy łagodną jest możliwe dopiero 
po badaniu histopatologicznym. Celem pracy było uzasadnienie celowości używania terminu „podejrzenie nowotworu pęcherzykowego” 
w diagnostyce cytologicznej raka tarczycy.
Materiał i metody: Poddano analizie 352 wyniki BAC tarczycy wykonanych w Instytucie Onkologii (IO) w Gliwicach w latach 2010–2015 
i ich korelację z rozpoznaniem histopatologicznym. 
Wyniki: W IO rozpoznanie podejrzenie nowotworu pęcherzykowego (grupa IV wg Systemu Bethesda) postawiono pierwotnie 
w 352 przypadkach. Leczenie operacyjne podjęto po pierwszej BAC w 6 przypadkach uzyskując potwierdzenie nowotworu w 5 przypadkach 
w tym jednego raka pęcherzykowego. Powtórna BAC przeprowadzona u 90 pacjentów potwierdziła rozpoznanie grupy IV w 53 przypadkach. 
Trzecią BAC przeprowadzono u 26 chorych, uzyskując kolejnych 14 rozpoznań grupy IV. Leczeniu operacyjnemu poddano 26 pacjentów na 
352 rozpoznania nowotworu pęcherzykowego, uzyskując potwierdzenie nowotworu w 19 przypadkach, co stanowi 73% w tym raka 5 razy. 
Wnioski: Wysoka dodatnia wartość predykcyjna PPV = 73% rozpoznania „podejrzenie nowotworu pęcherzykowego” uzasadnia podjęcie 
leczenia operacyjnego w każdym przypadku tego rozpoznania. (Endokrynol Pol 2016; 67 (1): 17–22)
Słowa kluczowe: guzek tarczycy; rak tarczycy; biopsja aspiracyjna cienkoigłowa
Introduction
Fine Needle Aspiration (FNA) has had a well-established 
position as an important diagnostic method. In recent 
years, its usage has undergone some modifications. Its 
application in breast diagnostics is limited to changes 
that do not present radiologic features of malignancy, 
while those that receive BI-RADS 4 or more are man-
aged with core needle biopsy. In the diagnostics of soft 
tissue tumours it is used with restriction and/or for 
cell-block preparation. In the workup of thyroid nod-
ules FNA still plays a fundamental role. It is a method 
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The aim of the study was justification of purposefulness 
of using the term “Suspicious for Follicular Neoplasm” 
(SFN) in cytological diagnostics of thyroid carcinoma.
that allows quick and simple assessment of the risk of 
malignancy of the biopsied changes, and hence guides 
clinical management [1]. 
The classification of thyroid cytological diagnoses 
— the Bethesda System for Reporting Thyroid Cyto-
pathology (BSRTC) — translates the complicated and 
mysterious language of cytopathological descriptive re-
port into a straight and comprehensive form that eases 
the dialogue between the pathologist, the surgeon, and 
the endocrinologist. Moreover, the implementation of 
BSRTC allows comparison of data concerning the risk of 
malignancy between institutions and the assessment of 
the system’s effectiveness and capability [2–7] (Table I). 
BSRTC was discussed and developed in 2007 by 
cooperation between pathologists, surgeons, endocri-
nologists, and radiologists. The inspiration for building 
a thyroid cytological examination report was the system 
that operates in gynaecological cytology. The report of 
thyroid FNA compatible with the recommendations 
of BSRTC enables the specialties that take part in diag-
nostic and therapeutic process to communicate clearly 
[4]. The implementation of the BSRTC to routine use in 
various countries took place in various intervals. The 
proposition of Polish guidelines based on the original 
National Cancer Institute (NCI) BSRTC text with minor 
modifications was elaborated by The Polish Group of 
Endocrine Tumours, and presented to the Scientific 
Committee of the “Thyroid Cancer 2010” Conference, 
appointed collectively by all scientific societies that 
organised the conference [7]. 
“Follicular Neoplasm or Suspicious for Follicular 
Neoplasm” (FN or SFN) — diagnostic category IV (DC 
IV) of BSRTC — is a challenging group. We cannot de-
fine whether we are dealing with a benign or malignant 
neoplasm on the basis of cytological examination of 
a follicular neoplasm [1, 4, 7, 8]. The NCI recommends the 
use of terms “Follicular Neoplasm” and “Suspicious for 
Follicular Neoplasm” due to the fact that 25% of these 
nodules are not neoplasms at all [4]. This category cov-
ers changes described before as “Follicular/Oxyphilic 
Neoplasm” as well as “Follicular/Oxyphilic Tumour”. 
It should not cover changes in which there are nuclear 
features consistent with papillary carcinoma. The sus-
picion of oncocytic/oxyphilic neoplasm is aroused when 
there are at least 75% of oxyphilic cells. It carries a higher 
risk of malignancy than SFN. According to the NCI, the 
risk of malignancy for FN and SFN ranges between 15% 
and 30% [4]. In Poland, the experts set a lower thresh-
old of 5–20%, considering as DC IV only the diagnoses 
that are consistent with SFN category [7] (Table II). The 
diagnosis of SFN should be made in cases in which the 
pathologist predicts the necessity of surgical treatment 
for obtaining tissue material and establishing a final 
histopathological (HP) diagnosis [4, 7].
Table I. The Bethesda system for reporting thyroid 
cytopathology [4]
Tabela I. Klasyfikacja cytopatologii tarczycy według systemu 
Bethesda [4]
Diagnostic category Risk of 
malignancy 
(%)
Management plan
Non-diagnostic/unsatisfactory
Limited cellularity or a cellular
Technically compromised
Cyst fluid only
1–4 Repeat FNA with 
ultrasound guidance
Benign
Adenomatous or colloid nodule 
Chronic lymphocytic thyroiditis 
Other 
0–3 Clinical follow-up
Atypia of undetermined 
significance (AUS)/follicular 
lesion of undetermined 
significance (FLUS)
5–15 Repeat FNA
Suspicious for a follicular 
neoplasm/follicular neoplasm
15–30 Surgical lobectomy
Suspicious for malignancy
Papillary carcinoma
Medullary carcinoma
Lymphoma
Metastatic neoplasm
Other
60–75 Surgical lobectomy or 
near total thyroidectomy
Malignant 97–99 Near total thyroidectomy 
Table II. FNA diagnosis and its risk of malignancy proposed 
in Polish guidelines (on the basis of [4, 7] with minor 
modifications) 
Tabela II. Wynik biopsji aspiracyjnej cienkoigłowej tarczycy 
i związane z nim ryzyko złośliwości zaproponowane w 
Polskich Rekomendacjach (zmodyfikowano na podstawie 
[4, 7])
BSRTC category Risk of malignancy
I — Non-diagnostic 5–10%
II — Benign < 1%
III — FLUS 5%
IV — SFN 5–20%
V — SM 30–50%
VI — Malignant 95–100%
BSRTC — The Bethesda System for Reporting Thyroid Cytopathology; FLUS — 
Follicular Lesion of Undetermined Significance; SFN — Suspicious for Follicular 
Neoplasm; SM — Suspicious for Malignancy
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Material and methods
A total of 16,656 FNA reports made in the Department of 
Tumour Pathology of Maria Sklodowska-Curie Memorial 
Cancer Centre and Institute of Oncology, Gliwice Branch 
from 2010 to 2015 were analysed and correlated with 
histopathological outcomes. All FNAs were performed 
in two-person teams of a pathologist and radiologist, 
under ultrasound guidance. The material was obtained 
by 25-gauge needles, and the smears were fixed in 95% 
alcohol and stained with haematoxylin-eosin (HE, 
Fig. 1). Usually we perform one FNA for each nodule 
(two or maximum three when a change does not subject 
to aspiration). All the evaluations and diagnoses were 
provided by the pathology specialists. Each test con-
tained a description of the site of the biopsy with the size 
of the nodule and ultrasound photography. The ques-
tionable cases were consulted by another pathologist.
Results
In our institution the diagnosis of SFN — DC IV accord-
ing to BSRTC was initially established in 352 cases (Fig. 2). 
Six patients were immediately subjected to operation 
after first FNA with this diagnosis, receiving the con-
firmation of a neoplasm in five cases (83% — 5/6): one 
follicular carcinoma and four follicular adenomas. The 
sixth patient was diagnosed with a hyperplastic nodule. 
Repeat (2nd) FNA performed in 90 patients confirmed 
SFN — DC IV in 53 cases. In this group, 14 patients were 
treated surgically, which resulted in the diagnoses of 
10 neoplasms (71% — 10/14): seven follicular adenomas 
(including five oxyphilic adenomas) and three cancers: 
two oxyphilic papillary carcinomas and one follicular 
carcinoma. Four patients obtained the diagnoses of 
benign changes: three hyperplastic nodules and one 
multinodular goiter. The third FNA was performed in 
26 patients who had DC IV in first FNA and DC II, DC 
III or DC IV in second and third FNA. In this group 
there were four resections performed, only in patients 
with three consecutive diagnoses of DC IV. The results 
of histopathological verifications in this group are two 
benign changes, which comprise 50%: one multinodu-
lar goitre and one oxyphilic hyperplastic nodule, and 
two benign neoplasms — oxyphilic follicular adenomas, 
which comprise 50%. Ten patients were subjected to 
Figure 1. Representative examples of Bethesda Diagnostic Category IV FNAs. Staining: haematoxylin-eosin
Rycina 1. Reprezentatywne przykłady rozmazów z biopsji aspiracyjnej cienkoigłowej tarczycy z kategorii IV klasyfikacji Bethesda. 
Barwienie: hematoksylina-eozyna
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fourth FNA. In this group there were two patients that 
had four consecutive DC IV diagnoses, and these two 
were subjected to surgery, which resulted in diagnoses 
of one oxyphilic papillary carcinoma and one follicular 
adenoma. The remaining eight patients (three with 
quadruple DC IV and the remainder that were given 
the diagnoses of DC IV, DC II, or DC I, alternately) did 
not undergo surgical procedure. Altogether, there were 
26 resections for 352 DC IV (7%), providing 19 diagnoses 
of neoplastic changes, which comprise 73%. Malignancy 
was reported in five patients, which comprise 19% of 
verified cases.
Discussion
Achieving the right diagnosis should not cause any 
problems if the material is of high quality: properly 
obtained, fixed, and stained. This process is essential 
for a comprehensive analysis of cytological specimens. 
Another key element is an experienced pathologist 
who deals with thyroid cytology on a daily basis. In 
our institution there were 16,656 FNAs performed in 
the last five years, giving the DC IV result in 352 ini-
tial examinations, which comprise 2.11%. Most of our 
patients had multiple FNAs, but repeat FNAs did not 
always confirm the initial diagnosis.
The literature data are varied. First of all, the 
elaborations that we encountered concern smaller 
study groups. Mondal et al. achieved 43 DC IV in 
1020 FNAs, which comprise 4.2% [9]. Nayar et al. in 
their study based on 5194 cases assessed the quan-
tity of DC IV at 4.7% [6]. Wu et al. showed a slightly 
higher percentage of DC IV, namely 8.4%, in a group 
of 1382 [5]. Theoharis et al. received more DC IV, 
378 for 3207 FNAs (11.7%) [10]. Srbova et al. in their 
analysis of 1310 FNA presented 220 DC IV (16.8%) 
[11]. A very high percentage (40%) was shown by 
Faquin et al. in a small group of 857 FNAs [12]. Radi-
cally different results were obtained by McElroy et 
al., who documented 1% of DC IV in 97 analysed 
FNAs in 2006, and after a review in 2012 the rate 
changed to 7% [13].
According to BSRTC recommendations, the diagno-
sis of SFN — DC IV should result in lobectomy [4]. Our 
attitude, as well as the surgeons’, is rather conservative. 
There is a tendency to believe that DC IV does not carry 
a high risk of malignancy, and aggressive therapy is 
not necessary. After 1st DC IV diagnosis at the study 
institution there were only six resections performed, 
giving the diagnosis of a neoplasm in 83% (5/6) cases. 
Repeat FNA had a 58% efficacy in confirming the initial 
diagnosis of DC IV (53/90).
DC I, DCII
n = 15 509
Total FNAs
n = 16 656
DC III
n = 395
DC IV
n = 352
DC V
n = 290
DC VI
n = 110
Observation
n = 256
Repeat 
(2nd) FNA
n = 90
Resection
n = 6
Neoplasm
n = 5
Neoplasm
n = 10
Carcinoma
n = 1
Carcinoma
n = 3
Carcinoma
n = 1
Adenoma
n = 1
Adenoma
n = 7
Restriction
n = 4
Benign change
n = 2
Restriction
n = 2
Observation
n = 8
Repeat 
(4th) FNA
n = 10
Repeat 
(3rd) FNA
n = 26
Benign change
n = 4
Observation
n = 13
Adenoma
n = 4
Restriction
n = 14
Hyperplastic
nodule
n = 1
2nd DC IV
n = 53
3rd DC IV
n = 14
Other DC
n = 37
Other DC
n = 12
Adenoma
n = 2
Figure 2. CONSORT diagram of the study group
Rycina 2. Diagram CONSORT analizowanej grupy pacjentów
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Ho et al. in their study tentatively divided the DC 
III (AUS/FLUS) into subgroups, naming the last one 
as “AUS/FLUS — cannot exclude follicular neoplasm”. 
On HP verification they obtained 24.4% of benign 
changes, and as much as 56.4% of malignant changes 
[1]. Harvey et al. compared the results of FNA before 
and after the implementation of BSRTC on groups 
of similar size (3302 and 3432), obtaining 309 and 
79 of DC IV, respectively. 70% from the 1st and 33% 
from the 2nd group were histopathologically veri-
fied, receiving the diagnoses of malignancy in 26% 
and 7%, respectively [14]. Moreover, they submitted 
an analysis of 11 studies comparing the number of 
surgical resections in DC IV category. The differences 
in the analysed cohorts are remarkable, the numbers 
range from 14% to 45% of operations. In our review 
altogether we achieved the diagnosis of 19 neoplasms, 
which comprise 73% (19/26 surgeries). In our material 
the risk of malignancy is 1.4% (5/352), and the risk of 
neoplasia is 5.4% (19/352).
BSRTC determines the risk of malignancy in detail 
[4–6]. An essential feature of DC IV is that correct clas-
sification of cytological image does not suggest the HP 
diagnosis. In this category, the premise is that the HP 
outcome is unknown. Only thorough HP evaluation 
one can assess the capsular and/or vascular invasion, 
which is the key feature of follicular carcinoma. The NCI 
estimates that 15–30% of changes with the diagnosis of 
FN or SFN would eventually be a cancer. In Poland, at 
implementation of BSRTC the rate has been assessed 
at 5–20% (for SFN only) by our experts [4, 7].
High risk of malignancy was described by Tepeoglu 
et al., at the level of 35% [8]. Similarly high results were 
presented by Yang et al. — 32.2% [15], Theoharis et 
al. — 34% [10], and Broome et al. — 36% [16]. Mondal 
reported a malignancy rate of 30.6% in the analysis of 
1020 FNA [9]. A lower rate was achieved by Srbova et 
al., who obtained a risk of malignancy of 23.6%, and 
a risk of neoplasia of 55% [11].
An unquestionably lower risk was demonstrated 
by Nayar et al. In their study based on 5194 cases the 
estimated risk of malignancy was 14%, and the risk 
of neoplasia — 75% [6]. Slightly higher rates were 
recorded by Wu et al.: 1382 FNAs, risk of malignancy 
at the level of 22% and the risk of neoplasia of 67% [5].
Faquin et al. (875 FNA) assessed the risk of malig-
nancy at 25%, and the risk of neoplasia at 43% [12]. 
Theoharis documented the risk of malignancy at the 
level of 43% (on a group of 3207 FNAs) [10].
The risk of neoplasia, and especially the risk of ma-
lignancy, presented by the researchers is greatly varied 
[2, 17, 18]. These major discrepancies may result from 
the number of analysed cases, from 97 FNAs [13] to 
more than 16 thousand (16,656 in our study). The con-
clusions drawn from a study based on a small group are 
always encumbered with a greater likelihood of error. 
The experience of cytopathologists is another factor that 
may affect the results; the accuracy of the evaluation 
diminishes the number of incorrect diagnoses. The veri-
fications in our study group were provided by a team 
of experienced pathologists who remained constant in 
the period covered by this study.
It is difficult to state whether the type of staining 
has an influence on the result. NCI does not impose 
any specific method of fixation or staining of the 
aspirates. In Poland, 99% of pathology departments 
use HE staining. Owing to this fact, we encounter no 
problems if any re-consultation is needed. Our experi-
ence with one institution that stains with the Giemsa 
method indicates that such images are confusing for 
pathologists educated on HE staining. The interpretive 
difficulties cause the need for repeat FNA to eliminate 
diagnostic doubts. 
Theoharis et al. based their analysis on a group of 
5897 FNA; most of the material was stained with Pa-
panicolau stain; part of the analysed cases were outside 
consultations stained with Papanicolau and HE [18]. 
Ho et al. [1] verified aspirates stained with Papanicolau 
and Giemsa, and Topeoglu studied specimens stained 
with Giemsa and HE, performing from 4 to 20 smears 
[8]. Part of the reviews are based on specimens stained 
with Giemsa and Papanicolau [8, 9, 19]. These studies 
often come from different medical centres, and the 
stains vary because of the need to collect a sufficiently 
large cohort. An overwhelming majority of researchers 
use Papanicolau stain [5, 6, 10, 14, 18, 20–28].
A smaller number of studies are based on specimens 
stained with Giemsa [8, 20, 29]. We did not encounter 
a study in which the aspirates were stained only with HE. 
We always prepare two specimens from one FNA, 
second and eventually third FNA is conducted only 
if we obtain very scanty material in first biopsy. This 
increases the chance for a correct diagnosis. Producing 
more specimens is unnecessary in our opinion, but the 
smearing glass slide is worth examining. Sometimes 
when the material is cell-rich and there is a lot of 
blood, the small amount that rests on the second slide 
is more adequate for assessment. We found studies in 
which there was only one specimen prepared, and the 
smearing slide was discarded. Srbova et al. performed 
from 2 to 10 smears stained with Giemsa [11]. Ohori 
et al. and Hyeaon et al. performed 2–4 FNAs [21, 30]. 
Our experience shows that high-quality diagnostic 
material can be obtained by one or, when we encounter 
problems in aspiration, two biopsies, to reduce the 
damage that is caused in the thyroid nodule, which 
impedes the assessment of capsular invasion (infiltra-
tion or artefact?).
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Analysing the publications, we noticed considerable 
differences regarding the qualification of the nodule 
to the FNA. Our institution is a comprehensive cancer 
centre and we perform FNA on all nodules, not only 
the ones with specific size or radiologic features of 
malignancy [26, 27]. 
The large amount of thyroid FNAs performed in our 
institution, the wide experience of the pathologist as 
well as radiologists, the possibility of consultation (there 
are 11 specialists working in our department, dealing, 
among others, with thyroid FNA), and the opportunity 
to verify the cytological diagnoses (we perform the 
intraoperative examinations and we obtain abundant 
post-operative material) lead to the high accuracy of 
our diagnoses. This entitles us to make the bold state-
ment that the diagnoses of the category “Suspicious for 
Follicular Neoplasm” are established precisely, and the 
patient’s management — if it is undertaken — is appro-
priate. Directing the patient to excision after receiving 
the diagnosis of this category is clearly indicated as the 
only way to determine the final diagnosis.
Conclusions
The high positive predictive value (PPV = 73%) of “Sus-
picious for Follicular Neoplasm” report justifies under-
taking surgical treatment in any case of this diagnosis.
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